The objective of the present study was to test the ability of OSU-03012 (2-amino-N-[4-[5-phenanthren-2-yl-3-(trifluoromethyl)pyrazol-1-yl]phenyl]acetamide), a novel and potent celecoxib-derivative, to impair endometriosis progression in in vitro and in vivo models based on its ability to indirectly block Y-box-binding protein 1 (YB-1) function. 12Z human endometriotic epithelial cells and sexually mature female C57BL/6J mice were treated with OSU-03012. Cellular proliferation was quantified by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromid assay. Expression of YB-1 and phosphorylated YB-1 in 12Z cells and endometriotic lesions was evaluated by Western blotting and immunohistochemistry (IHC). The IHC for proliferating cell nuclear antigen was performed. OSU-03012 treatment resulted in decreased YB-1 and its phosphorylated form in both in vitro and in vivo models. Endometriotic lesion size was significantly reduced in OSU-03012-treated mice (27.6 ± 4.0 mm3) compared to those from the control group (50.5 ± 6.9 mm3, P < .0001). A significant reduction in endometriotic epithelial cell proliferation was observed in endometriotic lesions exposed to OSU-03012 treatment (P = .0346). In conclusion, targeting YB-1 via OSU-03012 showed a potent antiproliferative effect on endometriotic epithelial cells in vitro and in a mouse model of disease.
GiudiceLC.Clinical practice. Endometriosis. N Engl J Med. 2010;362(25):2389–2398.
2.
BurneyROGiudiceLC. Pathogenesis and pathophysiology of endometriosis. Fertil Steril. 2012;98(3):511–519.
3.
MurkWAtabekogluCSCakmakH. Extracellularly signal-regulated kinase activity in the human endometrium: possible roles in the pathogenesis of endometriosis. J Clin Endocrinol Metab. 2008;93(9):3532–3540.
4.
NgôCNiccoCLeconteM. Protein kinase can control the progression of endometriosis in vitro and in vivo. J Pathol. 2010;222(2):148–157.
5.
RaiPShivajiS. The role of DJ-1 in the pathogenesis of endometriosis. PLoS One. 2011;6(3):e18074.
6.
CinarOSevalYUzYH. Differential regulation of Akt phosphorylation in endometriosis. Reprod Biomed Online. 2009;19(6):864–871.
7.
LaudanskiPSzamatowiczJKowalczukOKuźmickiMGrabowiczMChyczewskiL. Expression of selected tumor suppressor and oncogenes in endometrium of women with endometriosis. Hum Reprod. 2009;24(8):1880–1890.
8.
ZhangHZhaoXLiuSLiJWenZLiM. 17betaE2 promotes cell proliferation in endometriosis by decreasing PTEN via NFkappaB-dependent pathway. Mol Cell Endocrinol. 2010;317(1-2):31–43.
9.
LeconteMNiccoCNgôC. The mTOR/AKT inhibitor temsirolimus prevents deep infiltrating endometriosis in mice. Am J Pathol. 2011;179(2):880–889.
10.
MoscaEBarcellaMAlfieriRBevilacquaACantiGMilanesiL. Systems biology of the metabolic network regulated by the Akt pathway. Biotechnol Adv. 2012;30(1):131–141.
11.
SutherlandBWKucabJWuJ. Akt phosphorylates the Y-box binding protein 1 at Ser102 located in the cold shock domain and affects the anchorage-independent growth of breast cancer cells. Oncogene. 2005;24(26):4281–4292.
EliseevaIAKimERGuryanovSGOvchinnikovLPLyabinDN. Y-box-binding protein 1 (YB-1) and its functions. Biochem (Mosc). 2011;76(13):1402–1433.
14.
SilveiraCGTKrampeJRuhlandBDiedrichKHornungDAgicA. Cold shock domain family member YB-1 expression in endometrium and endometriosis. Hum Reprod. 2012;27(1):173–182.
15.
CrowderRJEllisMJ. Treating breast cancer through novel inhibitors of the phosphatidylinositol 3’-kinase pathway. Breast Cancer Res. 2005;7(5):212–214.
16.
KucabJELeeCChenCS. Celecoxib analogues disrupt Akt signaling, which is commonly activated in primary breast tumours. Breast Cancer Res. 2005;7(5):R796–R807.
17.
ToKZhaoYJiangH. The phosphoinositide-dependent kinase-1 inhibitor 2-amino-N-[4-[5-(2-phenanthrenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-acetamide (OSU-03012) prevents Y-box binding protein-1 from inducing epidermal growth factor receptor. Mol Pharmacol. 2007;72(3):641–652.
18.
GaoMYehPYLuYS. OSU-03012, a novel celecoxib derivative, induces reactive oxygen species-related autophagy in hepatocellular carcinoma. Cancer Res. 2008;68(22):9348–9357.
19.
WangYCKulpSKWangD. Targeting endoplasmic reticulum stress and Akt with OSU-03012 and gefitinib or erlotinib to overcome resistance to epidermal growth factor receptor inhibitors. Cancer Res. 2008;68(8):2820–2830.
20.
WengSCKashidaYKulpSK. Sensitizing estrogen receptor-negative breast cancer cells to tamoxifen with OSU-03012, a novel celecoxib-derived phosphoinositide-dependent protein kinase-1/Akt signaling inhibitor. Mol Cancer Ther. 2008;7(4):800–808.
21.
LeeTXPackerMDHuangJ. Growth inhibitory and anti-tumour activities of OSU-03012, a novel PDK-1 inhibitor, on vestibular schwannoma and malignant schwannoma cells. Eur J Cancer. 2009;45(9):1709–1720.
22.
MateoJDe BonoJSRamanathanRK. A first-in-human phase I trial of AR-12, a PDK-1 inhibitor, in patients with advanced solid tumors. J Clin Oncol. 2013;31(suppl; abstr 2608).
23.
ZeitvogelABaumannRStarzinski-PowitzA. Identification of an invasive, N-cadherin-expressing epithelial cell type in endometriosis using a new cell culture model. Am J Pathol. 2001;159(5):1839–1852.
24.
SilveiraCGFinasDHunoldP. L1 cell adhesion molecule as a potential therapeutic target in murine models of endometriosis using a monoclonal antibody approach. PLoS One. 2013;8(12):e82512.
25.
BanuSKLeeJStarzinski-PowitzAAroshJA. Gene expression profiles and functional characterization of human immortalized endometriotic epithelial and stromal cells. Fertil Steril. 2008;90(4):972–987.
26.
BanuSKStarzinski-PowitzASpeightsVOBurghardtRCAroshJA. Induction of peritoneal endometriosis in nude mice with use of human immortalized endometriosis epithelial and stromal cells: a potential experimental tool to study molecular pathogenesis of endometriosis in humans. Fertil Steril. 2009;91(5 suppl):2199–2209.
27.
GuCOyamaTOsakiTKohnoKYasumotoK. Expression of Y box-binding protein-1 correlates with DNA topoisomerase IIalpha and proliferating cell nuclear antigen expression in lung cancer. Anticancer Res. 2001;21(4A):2357–2362.
28.
SchönthalAHChenTCHofmanFMLouieSGPetasisNA. Celecoxib analogs that lack COX-2 inhibitory function: preclinical development of novel anticancer drugs. Expert Opin Investig Drugs. 2008;17(2):197–208.
29.
OlivaresCBilotasMBuquetR. Effects of a selective cyclooxygenase-2 inhibitor on endometrial epithelial cells from patients with endometriosis. Hum Reprod. 2008;23(12):2701–2708.
30.
LiuJQinCKLvWZhaoQQinCY. OSU-03012, a non-cox inhibiting celecoxib derivative, induces apoptosis of human esophageal carcinoma cells through a p53/Bax/cytochrome c/caspase-9-dependent pathway. Anticancer Drugs. 2013;24(7):690–698.
31.
RomeoYZhangXRouxPP. Regulation and function of the RSK family of protein kinases. Biochem J. 2012;441(2):553–569.
32.
Abu-AsabMZhangMAminiDAbu-AsabNAmriH. Endometriosis gene expression heterogeneity and biosignature: a phylogenetic analysis. Obstet Gynecol Int. 2011;2011:719059.
33.
StratfordALFryCJDesiletsC. Y-box binding protein-1 serine 102 is a downstream target of p90 ribosomal S6 kinase in basal-like breast cancer cells. Breast Cancer Res. 2008;10(6):R99.
34.
ShenHXuWLuoW. Upregulation of mdr1 gene is related to activation of the MAPK/ERK signal transduction pathway and YB-1 nuclear translocation in B-cell lymphoma. Exp Hematol. 2011;39(5):558–569.
35.
WeigelMTKrämerJSchemC. Differential expression of MMP-2, MMP-9 and PCNA in endometriosis and endometrial carcinoma. Eur J Obstet Gynecol Reprod Biol. 2012;160(1):74–78.
36.
IseTNagataniGImamuraT. Transcription factor Y-box binding protein 1 binds preferentially to cisplatin-modified DNA and interacts with proliferating cell nuclear antigen. Cancer Res. 1999;59(2):342–346.
37.
ChangYWMaiRTFangWHLinCCChiuCCWu LeeYH. YB-1 disrupts mismatch repair complex formation, interferes with MutSα recruitment on mismatch and inhibits mismatch repair through interacting with PCNA. Oncogene. 2014;33(43):5065–5077. doi:10.1038/onc.2013.450.
38.
LashamAPrintCGWoolleyAGDunnSEBraithwaiteAW. YB-1: oncoprotein, prognostic marker and therapeutic target?Biochem J. 2013;449(1):11–23.
39.
LawJHLiYToK. Molecular decoy to the Y-box binding protein-1 suppresses the growth of breast and prostate cancer cells whilst sparing normal cell viability. PLoS One. 2010;5(9):pii: e12661.
40.
ChatterjeeMRancsoCStuhmerT. The Y-box binding protein YB-1 is associated with progressive disease and mediates survival and drug resistance in multiple myeloma. Blood. 2008;111(7):3714–3722.
41.
LeeCDhillonJWangMY. Targeting YB-1 in HER-2 overexpressing breast cancer cells induces apoptosis via the mTOR/STAT3 pathway and suppresses tumor growth in mice. Cancer Res. 2008;68(21):8661–8666.
42.
GaoYFotovatiALeeC. Inhibition of Y-box binding protein-1 slows the growth of glioblastoma multiforme and sensitizes to temozolomide independent O6-methylguanine-DNA methyltransferase. Mol Cancer Ther. 2009;8(12):3276–3284.
43.
FotovatiAAbu-AliSWangPS. YB-1 bridges neural stem cells and brain tumor-initiating cells via its roles in differentiation and cell growth. Cancer Res. 2011;71(16):5569–5578.
44.
LashamASamuelWCaoH. YB-1, the E2F pathway, and regulation of tumor cell growth. J Natl Cancer Inst. 2012;104(2):133–146.
45.
LashamAMoloneySHaleT. The Y-box-binding protein, YB1, is a potential negative regulator of the p53 tumor suppressor. J Biol Chem. 2003;278(37):35516–35523.
Seton-RogersS. Therapeutics: siRNAs jump the hurdle. Nat Rev Cancer. 2012;12(56):376–377.
48.
YamamotoSIyodaTKitaSYamadaTIwamotoT. OSU-03012, a novel celecoxib derivative, induces cell swelling and shortens action potential duration in mouse ventricular cells. Biomed Res. 2010;31(6):413–417.
49.
SargeantAMKleinRDRengelRC. Chemopreventive and bioenergetic signaling effects of PDK1/Akt pathway inhibition in a transgenic mouse model of prostate cancer. Toxicol Pathol. 2007;35(4):549–561.
